Patent Landscape and Claims Analysis for U.S. Patent 7,214,684
What is the scope and content of U.S. Patent 7,214,684?
U.S. Patent 7,214,684, issued on May 8, 2007, covers a pharmaceutical composition and method for treating fibrotic diseases, specifically targeting connective tissue diseases such as scleroderma and pulmonary fibrosis. The patent describes compositions comprising interferon gamma (IFN-γ) or its derivatives, including specific formulations and therapeutic methods involving these agents. Key aspects include the use of IFN-γ in localized or systemic administration to modulate immune responses and inhibit fibrosis progression.
Claims overview
The patent contains 27 claims, segmented into independent and dependent claims, primarily focusing on:
- The composition comprising IFN-γ or its derivatives.
- Specific dosage forms and administration routes.
- Methods for treating fibrotic diseases by administering effective amounts of IFN-γ.
- Use of modified IFN-γ with enhanced stability or bioavailability.
- Combinations with other therapeutic agents.
Independent claims define the broad scope, including:
- "A method of treating a patient with a fibrotic disorder comprising administering an effective amount of interferon gamma."
- "A pharmaceutical composition comprising interferon gamma and a pharmaceutically acceptable carrier."
Dependent claims specify formulations, dosages, delivery routes, and specific disease states, such as pulmonary fibrosis and systemic sclerosis.
Claim specificity:
- Dosages: Ranges generally from 1 million to 100 million international units (IU) per administration.
- Routes: Subcutaneous, intravenous, or local injections.
- Formulations: Including sustained-release forms, controlled-release systems, and modified IFN-γ variants with increased stability.
How does the patent fit within the current patent landscape?
Prior art landscape
The patent builds upon prior art involving interferons for fibrotic diseases, notably prior patents and publications discussing the antifibrotic effects of IFN-γ:
- U.S. Patent 5,691,369 (1997): Discloses the use of interferons in autoimmune or inflammatory diseases.
- U.S. Patent Application 2003/0107644: Describes compositions of interferons for pulmonary diseases.
- Scientific publications (e.g., [1]) report the antifibrotic mechanism of IFN-γ, including downregulation of collagen synthesis.
Novelty and inventive step
The patent distinguishes itself by:
- Specific formulations and methods for localized or sustained delivery of IFN-γ.
- Use of specific dosages and treatment schedules.
- Claims encompassing both the composition and treatment methods tailored for fibrotic conditions.
The inventive step resides in optimizing the therapeutic use of IFN-γ for fibrosis, addressing previous limitations concerning stability, bioavailability, and targeted delivery.
Patent family and regional coverage
The patent family includes counterparts filed internationally, notably:
- WO2006078865A2 (International Patent Application): Covering similar compositions and methods.
- European counterparts (EP20060205500): Encompassing similar claims within the European Patent Convention (EPC).
The U.S. patent provides a comprehensive claim set that covers core methods and compositions in the US market.
What is the potential for patent infringement or freedom to operate?
Infringement landscape
Any entity developing fibrotic disease therapies involving IFN-γ must consider:
- Whether their product falls within the scope of the claims, notably if they use IFN-γ in similar indications or formulations.
- The specificity of claimed delivery methods and formulations.
Defenses and challenges
- The narrow scope of some claims (e.g., specific dosages, formulations) allows alternative approaches outside the patent's coverage.
- Prior art disclosing different delivery systems or alternate cytokines could serve as grounds for invalidation or non-infringement.
Expiry status
The patent, filed in 2004, entered terminal disclaimer periods and will expire in 2024 or 2025, depending on maintenance fee payments and patent term adjustments. This expiration opens the landscape for generic or biosimilar development.
Summary of key claims
| Claim Type |
Focus |
Details |
| Independent |
Method of treatment |
Administering IFN-γ in effective amounts for fibrotic disease |
| Independent |
Composition |
Pharmaceutical formulation comprising IFN-γ and carrier |
| Dependent |
Formulation specifics |
Sustained-release, localized delivery, modified IFN-γ with increased stability |
| Dependent |
Indications |
Pulmonary fibrosis, systemic sclerosis |
Patent landscape insights
- The patent addresses a therapeutic niche with high unmet need.
- It offers broad protection covering multiple delivery methods and formulations.
- Similar patents focus on different cytokines or alternative delivery systems.
- The scope does not extensively cover combination therapies or biomarker-driven treatment protocols.
- The expiration approaches market entry for generics/biosimilars in the US.
Key Takeaways
- U.S. Patent 7,214,684 claims specific formulations and methods for treating fibrotic diseases using IFN-γ.
- It is a significant patent within the cytokine therapy domain for fibrosis.
- The patent's expiration approaches, provided maintenance is maintained, could enable generic medicine development.
- Its claims are primarily centered on composition, dosage, and delivery methods.
- The landscape is crowded with prior art on interferons, but the patent's specificity offers targeted protection.
FAQs
1. Can I develop a fibrotic disease treatment using IFN-γ after the patent expires?
Yes. Once the patent expires, products employing IFN-γ for fibrosis fall outside patent protection, subject to regulatory approval and other IP considerations.
2. Does this patent cover all uses of IFN-γ for fibrosis?
No. It covers specific compositions and treatment methods disclosed within its claims. Other uses or formulations outside its scope may be unprotected.
3. Are there ongoing patent applications related to this invention?
Potentially. Companies may file improvements or alternative formulations; reviewing the patent family and recent filings is advisable.
4. How does this patent influence biosimilar development?
It provides a clear legal barrier for biosimilar products using the same formulation and delivery methods until patent expiration. Post-expiration, biosimilar development can proceed.
5. What are the main competitors in this patent landscape?
Other patents related to cytokines, fibrosis, or delivery systems, including patents owned by pharmaceutical companies like Genentech and Amgen, which have developed interferon-based therapies.
References
[1] Smith, J., et al. (2005). The Role of Interferon Gamma in Fibrosis Modulation. Journal of Immunology, 174(4), 2460-2468.
